KURA ONCOLOGY, INC. Income Tax Expense
KURA ONCOLOGY, INC. (KURA) reported Income Tax Expense of $5.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-12
- KURA ONCOLOGY, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $5.00K.
- KURA ONCOLOGY, INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $8.00K, a 96.46% decline year-over-year.
- KURA ONCOLOGY, INC. income tax expense (benefit) for the quarter ending 2025-12-31 was $71.00K.
- KURA ONCOLOGY, INC. income tax expense (benefit) for the quarter ending 2025-09-30 was $0.00.
- KURA ONCOLOGY, INC. income tax expense (benefit) for fiscal 2025 was $297.00K, a 85.28% decline from fiscal 2024.
- KURA ONCOLOGY, INC. income tax expense (benefit) for fiscal 2024 was $2.02M.
- KURA ONCOLOGY, INC. income tax expense (benefit) for fiscal 2023 was $0.00.
- KURA ONCOLOGY, INC. income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 4 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $5.00K 10-Q · filed 2026-08-12 | $13.00K 10-Q · filed 2026-08-12 | $84.00K derived: sum of 3 quarters · filed 2026-08-12 | $84.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $8.00K 10-Q · filed 2026-05-12 | $79.00K derived: sum of 2 quarters · filed 2026-05-12 | $79.00K derived: sum of 3 quarters · filed 2026-05-12 | $79.00K derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $71.00K derived: sum of 2 quarters · filed 2026-03-05 | $71.00K derived: sum of 3 quarters · filed 2026-08-12 | $297.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $226.00K 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $226.00K 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | $226.00K 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | $2.02M 10-K · filed 2026-03-05 | ||||
| 2023-12-31 | $0.00 10-K · filed 2026-03-05 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $0.00 10-K · filed 2018-03-12 | ||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-14 | ||||
| 2014-12-31 | $0.00 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |